Veracyte (VCYT)
(Real Time Quote from BATS)
$35.16 USD
+1.40 (4.15%)
Updated Sep 19, 2024 03:20 PM ET
1-Strong Buy of 5 1
F Value A Growth C Momentum C VGM
Company Summary
Headquartered in San Francisco, CA, Veracyte is a global diagnostics company that provides clinicians valuable insights to diagnose and treat cancer. The company has a wide array of advanced genomic tests that leverage deep scientific, clinical and machine learning expertise and other capabilities. Presently, the portfolio includes Afirma (for thyroid cancer), Decipher Prostate (prostate cancer), Prosigna (breast cancer), Envisia (interstitial lung diseases) and Decipher Bladder (bladder cancer), with additional tests in development.
These high-performing tests improve diagnostic, prognostic and treatment decisions in cancer and other challenging diseases, helping patients avoid unnecessary procedures and reduce ...
Company Summary
Headquartered in San Francisco, CA, Veracyte is a global diagnostics company that provides clinicians valuable insights to diagnose and treat cancer. The company has a wide array of advanced genomic tests that leverage deep scientific, clinical and machine learning expertise and other capabilities. Presently, the portfolio includes Afirma (for thyroid cancer), Decipher Prostate (prostate cancer), Prosigna (breast cancer), Envisia (interstitial lung diseases) and Decipher Bladder (bladder cancer), with additional tests in development.
These high-performing tests improve diagnostic, prognostic and treatment decisions in cancer and other challenging diseases, helping patients avoid unnecessary procedures and reduce time in finding appropriate treatment. In the United States, Veracyte offers tests through its central laboratories and makes the tests accessible to patients worldwide by collaborating with local labs.
The company recognizes revenues from three sources:
Testing revenues (90.4% of total revenues in 2023, up 30.3% from 2022): Upon delivery of the test results, the company bills for testing services considering factors such as payer reimbursement history, contracts and coverage.
Product revenues (4.3% of 2023 revenues; up 23.4%): Includes revenues from Prosigna breast cancer assay, the nCounter Analysis System (acquired from Nanostring Technologies, Inc. in 2019) and related diagnostic kits.
Biopharmaceutical and other revenues (5.2% of 2023 revenues; down 43.2%): Includes revenues from licensing or providing access to the company’s assets and services, including testing and contract manufacturing.
The company’s 2021 acquisition of Decipher Biosciences expanded its genomic testing menu into urologic cancers and provided Decipher GRID (Genomic Resource for Intelligent Discovery) — a platform and database that helps drive biopharmaceutical partnerships, key opinion leaders (KOL) engagement and pipeline development in urologic cancers.
In the same year, Veracyte acquired HalioDx, which enabled it to produce its own in vitro diagnostic (IVD) test kits for use on the nCounter Analysis System. Veracyte intends to migrate the manufacture of the test kits for the nCounter from NanoString to HalioDx.
General Information
Veracyte, Inc
6000 SHORELINE COURT SUITE 300
SOUTH SAN FRANCISCO, CA 94080
Phone: 650-243-6300
Fax: 650-243-6301
Email: investors@veracyte.com
Industry | Medical - Instruments |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/5/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 0.02 |
Current Year EPS Consensus Estimate | 0.14 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 11/5/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 33.76 |
52 Week High | 35.51 |
52 Week Low | 18.61 |
Beta | 1.66 |
20 Day Moving Average | 705,578.50 |
Target Price Consensus | 32.83 |
4 Week | 6.73 |
12 Week | 50.04 |
YTD | 22.72 |
4 Week | 6.78 |
12 Week | 46.30 |
YTD | 4.19 |
Shares Outstanding (millions) | 76.81 |
Market Capitalization (millions) | 2,593.18 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 241.14 |
Trailing 12 Months | 160.76 |
PEG Ratio | NA |
vs. Previous Year | 350.00% |
vs. Previous Quarter | 1,600.00% |
vs. Previous Year | 26.69% |
vs. Previous Quarter | 18.16% |
Price/Book | 2.28 |
Price/Cash Flow | 363.74 |
Price / Sales | 6.49 |
6/30/24 | 1.52 |
3/31/24 | -1.42 |
12/31/23 | -2.02 |
6/30/24 | 1.41 |
3/31/24 | -1.33 |
12/31/23 | -1.89 |
6/30/24 | 4.44 |
3/31/24 | 5.00 |
12/31/23 | 4.66 |
6/30/24 | 4.17 |
3/31/24 | 4.69 |
12/31/23 | 4.40 |
6/30/24 | 4.13 |
3/31/24 | -4.07 |
12/31/23 | -5.96 |
6/30/24 | -13.52 |
3/31/24 | -18.16 |
12/31/23 | -20.61 |
6/30/24 | -13.71 |
3/31/24 | -18.76 |
12/31/23 | -21.22 |
6/30/24 | 14.81 |
3/31/24 | 14.63 |
12/31/23 | 14.30 |
6/30/24 | 7.01 |
3/31/24 | 7.63 |
12/31/23 | 7.94 |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
12/31/23 | 0.00 |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
12/31/23 | 0.00 |